title: Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.
abstract: Sunitinib is an oral antityrosine kinase inhibitor that has antiangiogenic and antitumor activities. It has been approved for the treatment of advanced RCC and for imatinib-refractory gastrointestinal stromal tumors (GIST). Tumor lysis syndrom can occur in solid tumors. We report a case of patient with metastatic RCC treated with sunitinib with a diagnosis of tumor lysis syndrome.
authors: Institut Gustave Roussy, Département de Médecine, Villejuif, France.
authors: Judith
authors: J
authors: Michels
authors: Nathalie
authors: N
authors: Lassau
authors: Marine
authors: M
authors: Gross-Goupil
authors: Christophe
authors: C
authors: Massard
authors: Arnaud
authors: A
authors: Mejean
authors: Bernard
authors: B
authors: Escudier
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use*; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed; D015275:Tumor Lysis Syndrome / Q000000981:diagnostic imaging / Q000209:etiology*; D014463:Ultrasonography
chemical_list: D020533:Angiogenesis Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib